Thursday 02 December 2021

ITMO Cancer de l'Alliance nationale pour les sciences de la vie et de la santé (AVIESAN) : Subvention pour l’acquisition d’Équipement pour la recherche en cancérologie


 

Objectifs : Les équipements disponibles dans les laboratoires, et tout particulièrement sur les plateformes de recherche, sont cruciaux pour la compréhension des mécanismes de développement des cancers. L'objectif de cet appel est de permettre l'acquisition d'équipements semi-lourds et lourds dans les laboratoires et les plateformes de recherche indispensables au développement de projets de recherche ambitieux dans le domaine de la cancérologie, de favoriser les interactions entre les équipes et de renforcer l'attractivité et la place des équipes françaises sur la scène internationale dans ce domaine. L’effet structurant est donc un critère important.

Date limite de candidature :2 décembre 2021 (17h00)

Le site EVA3 est l’outil de dépôt en ligne : https://www.eva3.inserm.fr

Les demandes concerneront l’achat d’Équipements contribuant à l’activité des unités de recherche ou des plateformes mutualisées et/ou labellisées (IBiSA*, PIA, etc). 

Le présent Appel à Projets couvre tous les champs de la recherche en cancérologie. Compte tenu de la nature des financements (Stratégie Décennale de lutte contre les cancers 2021-2030), les Projets pour lesquels seront acquis les Équipements doivent être clairement centrés sur ce domaine de recherche, mais peuvent inclure des équipes - et des axes complémentaires - dont le domaine principal de recherche n’est pas l’oncologie. La demande peut porter sur l’acquisition d’un Équipement totalement nouveau sur le site, ou sur la jouvence d’un Équipement déjà présent. Dans ce dernier cas, la demande devra démontrer le saut technologique et l’effet structurant de l’Équipement neuf. 

Les demandes peuvent concerner des Équipements semi-lourds (entre 50 000 € et 134 999 € Prix Unitaire HT hors frais généraux, frais annexes1 compris) et lourds (entre 135 k€ et 1 M€ Prix Unitaire HT hors frais généraux, frais annexes compris).

Dans le cas d’Équipements lourds, un co-financement (selon l’échelle ci-dessous) devra être d'ores et déjà acquis au moment du dépôt de dossier. 

 Ce co-financement pour un Équipement lourd doit être acquis lors du dépôt du dossier selon l’échelle suivante :

o De 135 000 € à 449 999 €  : 33 % de co-financement acquis 

o De 450 000 € à 749 999 €  : 60 % de co-financement acquis

o De 750 000 € à 1 000 000 € : 70 % de co-financement acquis

Pour chaque demande de financement soumise, il ne peut y avoir qu’un/e (1) seul/e Coordinateur/trice de la demande et un (1) seul Organisme gestionnaire. Chaque Équipement ne peut faire l’objet que d’une

(1) demande de financement au titre de ce programme. Chaque demande ne peut porter que sur un (1) Équipement.

Est considérée comme inéligible toute demande concernant :

 L'installation de laboratoire ou de plateforme

o Les travaux d’aménagement de locaux

o Plusieurs Équipements distincts

o Du consommable relié à l’utilisation de l’Équipement

o Les frais liés à la maintenance de l’Équipement

1 Les frais annexes comprennent : la livraison, l’installation et la part de TVA non récupérable par l’Organisme gestionnaire. La maintenance ne fait pas partie des frais annexes et ne sera pas remboursée.

https://sp2013.inserm.fr/sites/eva/appels-a-projets/pca/Documents/Equipement%202022%20Texte%20de%20l%27AAP.pdf

https://sp2013.inserm.fr/sites/eva/appels-a-projets/pca/Pages/pcaeqt.aspx

Friday 03 December 2021

Alzheimer’s Drug Discovery Foundation (ADDF): Neuroimaging and CSF Biomarker Development Program  


                                                                                                                                                                https://www.alzdiscovery.org/research-and-grants/funding-opportunities/biomarkers

Letters of intent (LOI) are accepted and reviewed on a rolling basis during four cycles each year, with corresponding deadlines for invited full proposals (IFP)

LOI: February 5, 2021   IFP: April 16, 2021                           

LOI: May 28, 2021        IFP: July 30, 2021

LOI: October 1, 2021   IFP: December 3, 2021

 

Average Award: Up to $600,000 based on stage and scope of research.

Average Duration: One year with potential for follow-on funding. Multi-year proposals can be considered.

Allowable costs:

Only direct costs are allowed.

The ADDF seeks to fulfill its mission by providing funding for drug discovery and development projects.

  • ADDF funding may be provided for approved personnel costs, supplies (e.g., consumables, chemicals, animals), small non-durable equipment up to $2,500, consultants, and patient costs related to clinical trials.
  • ADDF funding is not provided for indirect costs/overhead, capital equipment, equipment service contracts, publication costs, or travel (unless travel is pre-approved under special circumstances).

The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

Specifically, this RFP focuses on:

  • developing novel PET ligands for clinical trials
  • supporting novel CSF biomarkers
  • validating established MRI approaches in larger cohorts

Peripheral biofluids and digital approaches are supported through the Diagnostics Accelerator RFP.

Novel biomarkers of neuroinflammation, synaptic integrity, autophagy and TDP-43 are high priority. Other target areas of interest include:

  • Neuronal loss
  • Vascular injury and blood-brain barrier integrity
  • Mitochondria and metabolic function
  • Protein misfolding
  • Oxidative stress
  • White matter changes
  • Lewy body dementia
  • Other novel targets supported by compelling biological rationale and connection to disease

The ADDF has limited interest in CSF measures of amyloid and tau.

Friday 03 December 2021

The Alzheimer's Drug Discovery Foundation (ADDF): Diagnostics Accelerator-Digital Biomarkers Program


 

The Diagnostics Accelerator is accepting applications on a rolling basis.

Exploratory awards: up to approximately $250,000

Proof-of-principle awards: up to $500,000

Validation awards: Award amounts will be based on stage and scope of research

 

Platforms : A variety of digital platforms such as portables, sensors, or software are encouraged. The proposed platform should have the potential to be easily deployed at scale. Passive approaches to data collection are encouraged.

Examples of digital approaches include, but are not limited to:

  • Wearables devices (e.g., smart watch)
  • Mobile/tablet apps
  • Smart home systems
  • Virtual and augmented reality platforms
  • Desktop/web apps

The following is out of scope for this RFP:

  • Diagnostic hardware for traditional digital imaging platforms (e.g. optical coherence tomography, neuroimaging)
  • Proposals focused on speech and language biomarkers

Note: The DxA is currently developing a speech and language biomarker consortium. Proposals outside this effort will not be considered at this time.

Symptom Domains : The RFP encourages digital biomarkers emerging from one or more of the symptom domains below. Proposed approaches will be evaluated based on the existing evidence around the biological link of the symptom domain to disease and how measuring the proposed symptom domain will improve current screening or monitoring methods in patients.

Symptom domains of interest include, but are not limited to:

  • Cognition (e.g. memory, processing speed, executive function, or geolocation)
  • Activities of Daily Living (instrumental basic activities or higher order activities)
  • Motor function (e.g. gait, body motion, or fine motor skills including tapping, swiping, and tracing on touchscreens)
  • Sensory Acuity (e.g. hearing, smell)
  • Affect (e.g. mood, facial expression)
  • Sleep Patterns and Characteristics
  • Oculomotor (e.g. eye movement)
  • Pain Assessment
  • Autonomic Nervous Function (e.g. heart rate, galvanic skin response)

Combinations of these or other symptom domains with a clear link to the disease are also encouraged.

 

Three stages of projects will be supported through this program:
  1. Exploratory awards will support pilot studies that aim to test the utility of an existing digital technology for the first time in an Alzheimer's disease or related dementia population. These projects should already have preliminary human data from another disease indication. For example, a pilot study would test a wearable gait monitoring device that has been tested in subjects with multiple sclerosis and is now being proposed to test in patients at risk for Alzheimer's. Only proposals with evidence demonstrating their technology or prototype can reliably capture, process, store, and transfer data from a clinical population will be considered. A limited number of awards will be considered in this category.
    Generally, projects at this stage will be awarded up to approximately $250,000 based on stage and scope of research. However, this is not a cap and higher funding levels will be considered if the proposed budget is well justified.

 

  1. Proof-of-principle awards will support projects that demonstrate feasibility and/or verify that a certain approach has potential for use in Alzheimer's disease or related dementias. Preliminary data from human subjects with the proposed indication is expected. For example, the disruption of sleep is an early change seen in Alzheimer's disease and a proof-of-principle project testing a device that is capable of detecting the stages and fragmentation of sleep would build on preliminary data acquired in the proposed patient population and proposed context of use, in addition to expanding the number of patients (e.g. ~100-200 subjects) tested with the sleep tracking device. Data must be provided demonstrating that the technology or prototype is capable of the reliable capture, processing, storage, and transfer of valid data to test in the clinical population.
    Generally, projects at this stage will be awarded up to approximately $500,000 based on stage and scope of research. However, this is not a cap and higher funding levels will be considered if the proposed budget is well justified.

 

  1. Validation awards will support projects that require testing at a larger scale and access to patients of varying demographic diversity to demonstrate clinical relevance. The technology must be verified and validated. Data quantifying the accuracy, precision, consistency, and uniformity of the technology must be provided. Applicants will be required to address scalability considerations, clinical integration plans, and anticipated regulatory considerations and commercialization. Data sharing policies and standards, intellectual property restrictions, and standard operating procedures should be well defined. Validation studies should prioritize comparisons using existing gold standard approaches to diagnose and monitor such as neuroimaging and/or CSF measurements, as well as clinical tests such as cognition, but this is dependent on the context of use. These studies will require a comprehensive experimental plan with larger sample size (e.g. 500-1000+ subjects based on power analyses). Award amounts will be based on the stage and scope of the research.

Projects that succeed in the exploratory or proof-of-principle stage may be eligible for follow-on funding in the form of a validation award.

https://www.alzdiscovery.org/research-and-grants/funding-opportunities/diagnostics-accelerator-digital-biomarkers-program

 

Thursday 09 December 2021

NIH Funding Opportunities


NIH Funding Opportunities (Foreign Institutions are eligible to apply) / Financements NIH ouverts aux institutions non-US

Ensemble d'appels d'offres ouverts aux institutions non-US, on this page, a set of calls for proposals that are open to non-US institutions

Thursday 09 December 2021

The Michael J. Fox Foundation (MJFF) & the Edmond J. Safra Foundation: The Edmond J. Safra Fellowship in Movement Disorders


 

The Edmond J. Safra Fellowship in Movement Disorders aims to grow the global base of movement disorder specialists — neurologists with additional training in Parkinson's disease and other movement disorders — by training movement disorder clinician-researchers who can provide expert care and lead scientific advances. 

As the demand for movement disorder specialists increases, not enough neurologists are receiving vital training in Parkinson’s and related conditions. To address this need, The Michael J. Fox Foundation (MJFF), in collaboration with longtime partner the Edmond J. Safra Foundation, launched The Edmond J. Safra Fellowship in Movement Disorders. The program annually funds academic centers to each train a new movement disorder clinician-researcher over a two-year period and is growing an international, collaborative network of next-generation leaders in Parkinson’s research and care.

Deadline: December 9, 2021, 5 p.m. U.S. ET

Funding Available:

MJFF will award eight two-year fellowships $180,000 for each two-year fellowship ($90,000 per fellow per year)

Eligibility:

The program grants funding directly to academic centers, which then must identify and train a new movement disorder clinician-researcher over a two-year period. Grant support cannot be used for a fellow already enrolled or selected. The Edmond J. Safra Fellowship in Movement Disorders is open to academic centers worldwide. Previously awarded centers — except those that received an Edmond J. Safra Fellowship grant in the most recent funding cycle — are eligible to apply.

What information is required for submission?

Two application templates are provided (see “Application Guidelines”). One form requests information about the academic center’s previous experience training movement disorder clinician-researchers, research environment, clinical care center, departmental support, and leadership in building an inclusive, equitable and diverse environment for clinical care, research and education. The other gathers information about numbers of movement disorder clinician-researchers trained, faculty, patients seen per year, etc. 

Biographical sketches (NIH format) for five faculty members who will be active in the training program also are required.

https://www.michaeljfox.org/grant/edmond-j-safra-fellowship-movement-disorders

https://www.michaeljfox.org/sites/default/files/media/document/Application_The_Edmond_J__Safra_Fellowship_Class_of_2025_0.pdf

https://www.michaeljfox.org/sites/default/files/media/document/FAQs_The%20Edmond%20J.%20Safra%20Fellowship_2021.pdf

Friday 10 December 2021

The Simons Foundation Autism Research Initiative (SFARI): Targeted initiatives planned for 2021


 

SFARI is planning several targeted initiatives to be launched in 2021. Investigators whose projects are appropriate to the efforts described below should refrain from applying to the Pilot Award RFA:

 

  • Behavioral and Circuit Neuroscience Research Consortium Using SFARI Rat Models

SFARI has supported the development and characterization of genetically-modified rat models for autism. To enhance these efforts, SFARI intends to release a targeted RFA in mid-2021 for investigators to participate in a research consortium focusing on the strengths of the rat as an experimental model system. It is expected that participating investigators will demonstrate strong expertise in behavioral and/or circuit neuroscience, and actively contribute to the intellectual pursuits and open-science ethos of the research consortium.

 

  • Characterization of Autism BrainNet Postmortem Brain Tissue

Over the past five years, Autism BrainNet has amassed a large collection of postmortem brain tissue from individuals with and without autism that will allow for replication of previously published findings and new discoveries. The tissue and associated donors’ clinical data are currently available for distribution to approved researchers, and whole-genome sequencing of the tissue is underway. SFARI is anticipating a funding call for studies of this collection that will compare bulk-tissue and single-nucleus gene expression. Analyses may also include alternative splicing, RNA editing, non-coding RNAs, epigenetic modifications and/or proteomics.

 

  • Functional Analysis of Missense Mutations

The Functional Analysis of Missense Mutations RFA builds on a previous 2015 SFARI call for applications to carry out a range of functional analyses of missense mutations identified in high-penetrance autism risk genes. Proposals to be invited in this follow-up RFA may include (1) those that establish high-throughput pipelines of functional assays of many genes or (2) those that focus on a smaller number of genes but establish a comprehensive understanding of clinically relevant functional variation.

 

  • Genomic Analysis of the SPARK Cohort

The Genomic Analysis of the SPARK Cohort RFA follows up a previous SFARI RFA to analyze emerging exome and genome sequencing datasets of the SPARK cohort. The new call for applications will be offered in light of the substantial growth in the number of sequenced individuals in SPARK, as well as new opportunities to integrate these data with other cohorts in the service of ASD risk gene discovery.

 

  • Large-Scale Use of Induced Pluripotent Stem Cells to Elucidate ASD Biology

SFARI is creating a large induced pluripotent stem (iPS) cell resource from more than 100 participants in Simons Searchlight. With the advent of new methods that enable well-controlled, quantitative analysis on a large number of samples in parallel, this resource by itself or in combination with others presents a unique opportunity for large-scale, comparative studies across iPS cell lines with mutations in ASD-linked genes and multiple variants within one gene. We anticipate a targeted call for innovative proposals that take advantage of this resource to study genetic, molecular and cellular mechanisms of ASD later in 2021.

 

  • Targeted Molecular Therapies

SFARI currently supports about 10 groups working on projects related to antisense oligonucleotide (ASO) and gene therapy approaches, and organized a workshop on gene therapies for ASD in order to help identify key areas where additional funding could be most effective. We anticipate a targeted call for additional proposals in this area later in 2021.

 

  • The Microbiome in Autism

Over the last six months, SFARI has consulted with over 50 external researchers as part of an in-depth analysis of the state of the field in understanding the microbiome-gut-brain-autism axis. We are working with a small group of researchers to develop a framework for designing integrated multi-omic studies in this space, and depending on the results of that work, we anticipate making some type of funding call in this area later in 2021.

 

Over the next few months, we will be providing more information about our planned targeted initiatives via SFARI.org and the SFARI newsletter. To receive updates about SFARI news and funding opportunities, please subscribe to our newsletter. In the meantime, we welcome your feedback on the scientific priorities and procedures we should consider at sciencerfa@simonsfoundation.org.

 

https://www.sfari.org/2021/03/01/updates-to-sfaris-2021-requests-for-grant-applications/

Sunday 12 December 2021

Le plan France Relance et la préservation de l'emploi de R&D en santé.


 

Cette mesure permettra de conserver les capacités humaines de R&D des entreprises françaises en difficulté suite la crise sanitaire, en contribuant au financement de salaire de personnels, et en facilitant l’emploi de jeunes diplômés à travers des collaborations entre des laboratoires Inserm et les entreprises.

 

L’Inserm dispose ainsi d’un financement lui permettant de préserver ou de créer plus de 200 emplois R&D dans les entreprises ou ses laboratoires dans le domaine de la Santé. Inserm Transfert, la filiale de l'Institut dédiée à la valorisation, sera le point de contact des entreprises qui souhaitent bénéficier des crédits du plan France relance pour créer, relancer ou renforcer, des partenariats de recherche avec des équipes Inserm.

 

Un élément indispensable : un programme de recherche collaboratif

  • Un programme de recherche collaboratif encadré par un accord de collaboration est l’élément indispensable à la mise en œuvre du dispositif.

Préservation de l’emploi R&D grâce à 2 mesures :

  • Prise en charge d’une partie de la rémunération des personnels R&D du privé déjà en poste dans la société.
  • Recrutement de jeunes diplômés par l’Inserm.

https://www.inserm-transfert.fr/industriels/plan-france-relance/

https://www.inserm.fr/nous-connaitre/inserm-et-plan-france-relance/

Tuesday 14 December 2021

Autism Speaks


 

Autism Speaks, with generous support from the Royal Arch Research Assistance, anticipates funding three research projects focused on understanding, evaluating and/or treating individuals with central auditory processing disorder (CAPD), particularly as it relates to autism spectrum disorder (ASD).

The goal: To advance the clinical management of CAPD and associated neurobehavioral challenges, improving quality of life people with co-occurring ASD and CAPD.

 

Autism Speaks anticipates funding:

  • one pilot research award, up to US $60,000 for one year
  • one predoctoral fellowship award, up to US $40,000/yr for two years
  • one postdoctoral award, up to US $55,000/yr for two years

Focused on understanding, evaluating and/or treating individuals with central auditory processing disorder (CAPD), particularly as it relates to autism spectrum disorder (ASD)

 

Letter of Intent due: December 14, 2021

Applicants with approved LOIs will be invited to submit a full application by February 16, 2022.

https://www.autismspeaks.org/research

https://science.grants.autismspeaks.org/uploads/helpdocs/RAM_CAPD_RFA_2022.pdf

Tuesday 14 December 2021

ANR - NSF/Physics/MCB Lead Agency Opportunity at the Physics - Molecular and Cellular Biosciences Interface


 

The U.S. National Science Foundation (NSF) and the French Agence Nationale de la Recherche (ANR) have signed an agreement on Research Cooperation.

 

Timeline for Submissions:

NSF/PHY: December 14, 2021 (due by 5 p.m. submitter's local time)

ANR Registration: December 15, 2021 (due by 1 p.m. Paris time)

 

If a proposal is recommended for funding, the U.S. organization(s) will be supported by NSF/PHY and/or NSF/MCB, and the French organization(s) will be supported by ANR. NSF/PHY, NSF/MCB and ANR staff will review budgets to ensure that there are no duplications in funding.

 

The NSF Division of Molecular and Cellular Biosciences in the Directorate for Biological Sciences and Division of Physics in the Directorate for Mathematical and Physical Sciences (NSF/BIO and NSF/PHY) and the ANR are pleased to announce topical areas associated with the lead agency opportunity. In FY 2022 (October 2021-September 2022), NSF will serve as the lead agency for all proposals. It is expected that NSF and ANR will alternate as lead agency in subsequent years.

 

The lead agency opportunity allows U.S. and French researchers to submit a single proposal describing a project involving U.S. and French researchers, that will undergo a single review process by the lead agency, on behalf of NSF/MCB, NSF/PHY and ANR. In FY 2022, proposals will be accepted for U.S.-France collaborative projects in the areas of intersection between NSF/MCB, NSF/PHY and some of the research themes covered by the ANR's Generic call for proposals, 2022 edition G, as set out in this Dear Colleague Letter.

Proposals must address the priorities of each of the participating entities: ANR, NSF/MCB and NSF/PHY. Proposers must provide a clear rationale for the need for a U.S.-France collaboration, including the unique expertise and synergy that the collaborating groups will bring to the project. Proposers should note that the lead agency opportunity does not represent a new source of funding. Proposals will be assessed in competition with all others submitted to the priority areas and agency programs identified in this DCL, and outcomes will be subject to both success in merit review and the availability of funds from NSF/MCB, NSF/PHY and ANR.

 

Physics from Molecules to Cells

The emergence, evolution, dynamics and function of self-organized cellular systems stem from the interaction of biological components and the environment to yield robust, resilient and adaptive living systems. Through this DCL, NSF and ANR seek proposals that use multidisciplinary approaches that emphasize quantitative, predictive and theory driven science aimed at understanding mechanisms underlying these essential life processes at the molecular, subcellular and cellular scales. We are seeking proposals that integrate approaches from theoretical and experimental physics and biology to develop testable and quantitative understanding of biological questions. Projects providing innovative methodological or conceptual approaches to a biological question together with a strong theoretical physics component are strongly encouraged. Purely descriptive projects without predictive quantitative components are of low priority. Projects that leverage unique resources and capabilities of partners in the U.S. and France will be given priority. Projects that focus on the etiology and pathogenesis of disease and projects that focus on tissue or organismal level problems are not appropriate for NSF/MCB and, therefore, would not be appropriate for this lead agency opportunity.

 

Contacts

Wilson Francisco, wfrancis@nsf.gov

Krastan Blagoev, kblagoev@nsf.gov

https://www.nsf.gov/pubs/2021/nsf21120/nsf21120.jsp?WT.mc_id=USNSF_25&WT.mc_ev=click

Wednesday 15 December 2021

La Fédération pour la Recherche sur le Cerveau (FRC) : Appel à Projets 2022 « L'adaptation du cerveau à son environnement »


 

La FRC et ses membres lancent leur Appel à Projets 2022 en recherche clinique et fondamentale en relation avec les pathologies neurologiques et psychiatriques sur le thème : « L'adaptation du cerveau à son environnement »

 

La FRC et ses membres lancent un Appel à Projets visant à préciser les mécanismes moléculaires et cellulaires à la base des adaptations (bonnes ou mauvaises) de notre cerveau à son environnement, et à explorer des applications diagnostiques ou thérapeutiques nouvelles à partir de ces connaissances scientifiques.

 

L’Appel à Projets concerne en particulier les situations suivantes :

  • Les adaptations du cerveau aux modifications liées aux comportements de vie (stress, isolement, traumatismes, conduites addictives, alimentation, exposition à des substances toxiques, activités physiques et intellectuelles, sommeil…).
  • Les solutions de compensation, de protection ou de remédiation face aux handicaps physiques, psychiques ou sensoriels.
  • Les adaptations du cerveau à des troubles des fonctions sensorielles (perte sensorielle, acouphènes, douleurs chroniques…).
  • Les adaptations spécifiques liées à l’âge (période précoce, adolescence, vieillissement).

Seront privilégiés :

  • Les projets de recherche transversale portant sur plusieurs pathologies, en accordant une attention particulière à celles qui sont dans le champ des associations membres de la FRC.
  • Les projets multidisciplinaires et translationnels impliquant plusieurs équipes fondamentales et/ou cliniques.

 

Budget :

Des subventions d’un montant de 80 000 euros chacune pourront être accordées pour une durée d’une ou deux années. Les subventions pourront être demandées pour financer de l’équipement, du fonctionnement, du personnel (vacations, gratifications de stage, 4ème année de thèse, contrat à durée déterminée de post-doctorant, ingénieur ou technicien).

 

Il est précisé que le porteur du projet doit être un chercheur ou clinicien statutaire affilié à une équipe de recherche labellisée (voir critères d’éligibilité), et que cette dernière ne peut déposer – comme porteur ou collaborateur financé – qu’un seul projet à l’Appel à Projets au cours de la même année. En effet, la FRC ne financera pas plusieurs fois la même année l’équipe d’un même responsable scientifique, qu’elle soit porteuse ou partenaire d’un projet.

 

La sélection des demandes de soutien s’effectuera en 2 phases, selon le calendrier suivant :

Phase 1 


Phase 2

  • Pour les candidatures présélectionnées, un projet détaillé (6 pages maximum) devra être soumis, ainsi qu’une liste de 10 publications récentes.
  • Ce dossier final devra parvenir à la FRC (email et papier) mi-février 2022.

 

https://mailchi.mp/frcneurodon/appel-projets-exceptionnel-frc-2457191?e=d066fe7941

Thursday 16 December 2021

ITMO Cancer de l'Alliance nationale pour les sciences de la vie et de la santé (AVIESAN) & l'ITMO Technologies de la Santé : PCSI


 

​​​​​​​Approches interdisciplinaires des processus oncogéniques et perspectives thérapeutiques : Apports à l’oncologie de la physique, de la chimie et des sciences de l’ingénieur

L’objectif général de cet appel à projets est de financer des projets fondés sur des concepts ou des outils de la physique, de la chimie ou des sciences de l’ingénieur, visant à générer des progrès scientifiques et technologiques en oncologie.

Le but de cet appel à projets est de mieux comprendre les maladies tumorales et d’améliorer le pronostic des patients en permettant des progrès significatifs dans les domaines de la compréhension des mécanismes de la cancérogenèse (initiation, progression, dissémination métastatique, résistance, …), du diagnostic et de la prise en charge thérapeutique des pathologies cancéreuses. Les démarches originales et innovantes avec prise de risque seront encouragées.

Deux types de projets seront éligibles :

  • des projets de courte durée destinés à établir des preuves de concept (18 mois). Le Projet doit comporter entre 2 et 4 équipes appartenant à au moins deux disciplines différentes. L’implication d’au moins une équipe du champ biologie ou médecine est recommandée mais pas obligatoire.
  • des projets d’envergure bâtis sur des preuves de concept déjà obtenues (36 mois). Le Projet doit comporter entre 2 et 4 équipes appartenant à au moins deux disciplines différentes. L’implication d’au moins une équipe du champ biologie ou médecine est recommandée mais pas obligatoire.

Montants des subventions
· Pour les Projets portant sur la génération de « Preuves de concept », le montant maximal alloué sera de 60 k€. Ce montant sera partagé au maximum par 3 équipes. Une quatrième équipe peut se joindre au consortium, mais elle ne sera pas financée.
· Pour les « Projets complets », les montants seront déterminés en fonction du Projet.
L’adéquation du budget prévisionnel, indiqué par le/la Coordinateur/trice scientifique, avec l’envergure du Projet proposé sera évaluée par le Comité d’évaluation et le budget éventuellement révisé. A noter qu’un budget trop conséquent par rapport à la moyenne des demandes reçues sera défavorablement pris en compte dans le classement final.

Une même équipe ne peut déposer qu’un seul dossier.

Le même projet ne peut pas être soumis aux appels MCMP ou MIC 2022.

Date limite de candidature : 16 décembre 2021, 17h

Le site EVA3 est l’outil de dépôt en ligne des projets : 

https://eva3-accueil.inserm.fr/sites/eva/appels-a-projets/pca/Pages/pcsi.aspx

https://www.inserm.fr/actualite/appel-projet-apport-oncologie-physique-chimie-et-sciences-ingenieur/

https://sp2013.inserm.fr/sites/eva/appels-a-projets/pca/Pages/pcsi.aspx

https://sp2013.inserm.fr/sites/eva/appels-a-projets/pca/Documents/PCSI%202022%20Guide%20Candidat.pdf

Pour les questions d’ordre scientifiques et techniques : cancerinserm.pcsi@inserm.fr
Pour les questions d’ordre financier : cancer.daf@inserm.fr
Pour les questions informatiques : eva@inserm.fr

Friday 17 December 2021

CurePSP: Venture Grant


 

Deadline: December 17, 2021

Amount: $100,000, up to 3 years.

https://www.psp.org/iwanttolearn/grants/

 

Thursday 23 December 2021

Funding opportunities from International Foundations


On this page discover the funding opportunities of international foundations according to your activity topics

 

Below the exel version

Monday 03 January 2022

La Fondation Bettencourt Schueller : Impulscience


 

La Fondation accompagne financièrement chaque projet sur une durée de 5 ans à hauteur de 2 millions d’euros, auxquels s’ajoutent la prise en charge des frais de gestion et la prime personnelle du chercheur.

 

Le premier appel à candidatures aura lieu en 2022.

 

Impulscience est ouvert aux chercheurs et chercheuses remplissant les conditions suivantes :

  • présenter un projet de recherche innovant dans les sciences de la vie ;
  • avoir répondu et avoir été sélectionné lors des appels à projets Starting, Consolidator ou Advanced de l’ERC de l’année précédente mais sans avoir obtenu le financement de l’ERC (classé A à l’issue de la seconde étape de l’évaluation ERC) ;
  • avoir moins de 50 ans au 1er janvier de l’année durant laquelle la candidature est évaluée par la Fondation Bettencourt Schueller et présenter sa candidature au minimum 5 ans après la date d’obtention du doctorat ;
  • travailler dans un laboratoire public en France au moment de la candidature ou au plus tard au moment du début du projet.

https://www.fondationbs.org/fr/sciences-de-la-vie/soutien-aux-chercheurs/impulscience

Monday 10 January 2022

The Simons Foundation Autism Research Initiative (SFARI): Analysis of Postmortem Brain Tissue from the Autism BrainNet Collection — Request for Applications


 

Deadline: January 10, 2022

Annual budget: $300,000-$1,000,000, for 2 years.

https://www.sfari.org/grant/analysis-of-postmortem-brain-tissue-from-the-autism-brainnet-collection-request-for-applications/

 

Friday 21 January 2022

EIT Health Call for proposals: Innovation projects and Education programmes


The publication of this call is the beginning of a journey connecting those who understand and can identify the needs with those who have the solution to ultimately deliver value to patients and citizens, as well as to our healthcare systems by and large.

See complete version

Tuesday 01 February 2022

The Focused Ultrasound Foundation


 

We fund high risk or clinically based investigator-initiated projects through the External Awards Program. We also fund projects in high-priority applications of FUS through the Brain Program, Cancer Immunotherapy Program, and Veterinary Program, including both invited and investigator-initiated projects.

Brain program: It is the ultimate goal of the Foundation's Brain Program to see focused ultrasound become a standard of care for the treatment of a range of neurological disorders, including movement disorders, brain tumors, epilepsy and stroke.

 

The External Awards Program provides funding for investigator-initiated clinical, preclinical, and early-stage research projects through a competitive peer-reviewed application process.

 

The program has two tracks:

* The Pre-Clinical Track is geared primarily towards preclinical studies and research projects that target a particular clinical indication or organ. It is meant to fund research that could lead the way to a new reimbursable clinical application for image-guided FUS within five to seven years.

 

*The High-Risk Track is intended for early-stage, high-risk, proof-of-concept research that, if successful, could have a profound impact on the field of focused ultrasound and that could change the way many conditions are treated.

 

**Additionally, the External Awards Program accepts abstracts for Clinical Trial funding requests. The abstract form for Clinical Trials is linked in the Materials section below. Funding for clinical trials is not limited to $100,000 and one year.

 

Funding: one-year awards totaling approximately $100,000

The Pre-Clinical Track typically does not fund large capital purchases, cannot fund overhead or institutional expenses, and will not fund the development of new focused ultrasound equipment

 

Application Process

Step 1: A one-page Research Abstract must be submitted at least two weeks prior to the program’s quarterly application deadlines (Feb. 1, May 1, Aug. 1, and Nov. 1).

Step 2: The Foundation will invite full Research Proposals from authors of approved Research Abstracts.

Funding decisions are returned to the applicant approximately three months after their application deadline.

 

https://fusfoundation.org/for-researchers/external-research-awards-program/apply-for-funding

https://fusfoundation.org/for-researchers/external-research-awards-program

 

Questions?

Please contact Matt Eames, PhD, Director of External Research, at meames@fusfoundation.org.

 

 

Monday 14 February 2022

The Leducq Foundation:  Call for International Networks of Excellence Program (INEP) 2021-2022


 

The Leducq Foundation has created the International Networks of Excellence in Cardiovascular and Neurovascular Research Program, (formerly the Transatlantic Networks of Excellence in Cardiovascular and Neurovascular Research Program) which promotes internationally collaborative basic, translational, and clinical research in cardiovascular and neurovascular disease. The principal aim of this program is to foster outstanding and innovative scientific research by bringing together international teams of researchers with complementary expertise and resources to work together on a common thematic problem. The proposals should aim to generate new knowledge with the potential to advance the diagnosis, prevention, and treatment of cardiovascular and/or neurovascular disease. Early career investigators play a vital role in these networks, which provide an excellent context for training and career development in cardiovascular and neurovascular research.

 

In the 2021-2022 application cycle, the Leducq Foundation will award four International Network of Excellence grants, each for an amount not to exceed U.S. $7,500,000 over five years.

 

Letter of Intent (LOI) Deadline: September 7, 2021

Notification of Application Status: November 1, 2021

Full Application Deadline: February 14, 2022

Scientific Advisory Committee Review: April 2022

Leducq Board of Directors Review: May 2022

Funding to Commence: January 1, 2023

 

With the International Network of Excellence (INE) Program, the Leducq Foundation looks to support original and outstanding research in the areas of the foundation’s mission, namely, cardiovascular and neurovascular disease. Applicants are encouraged to think innovatively and to propose bold new ideas.

 

Network activities should be oriented towards long-term goals, not at producing pre-defined results.

Leducq Foundation accepts applications in basic, translational, and clinical science, including collaborative “bench to bedside and back” programs.

 

Each network is built around an international research alliance involving two network coordinators, who must be located on different continents.

 

Interdisciplinary collaboration is particularly encouraged.

 

Size:

The size of the network may vary depending on the theme, on the type of research, and may not be determined fully at the outset. More important than the size of the network is the rationale for the inclusion of the members, and the case that is made for the collaborative benefit to be gained by their inclusion. At a minimum, a Leducq network should have three institutional members. As a general recommendation, the total number of institutions should not be greater than six, at which point the network becomes more difficult to manage. Applicants proposing to include more than six institutions in the network should discuss directly how the administrative and governance challenges associated with a larger network will be addressed. (For this purpose, INSERM units are considered separate institutions if they are at different universities and/or are administered by different INSERM délégations régionales.) All network applicants must demonstrate in the application how the composition of the network advances the scientific objectives of the research program.

 

International Network grants are not renewable. Members of concluding networks who wish to reapply with a team that consists of largely of the same participants, and with a theme similar to that of the existing network, are urged to present a new and original direction for research. All applications are considered on a de novo basis.

  • Network coordinators may not participate concurrently in any other Leducq network, in any capacity. Following the conclusion of the program of which they were the coordinators, they are ineligible to apply again to the International Networks of Excellence Program as a network coordinator, although they are eligible to participate as a member of another network. An exception is made for network members who, for whatever reason, have taken up the responsibility of network coordinator during the term of the network grant; they may apply to the foundation as the coordinator of a new network.
  • Network members may not participate in more than two Leducq International Networks concurrently. (This rule applies only to the 5-year term of the grant, and not to the no-cost extension period that networks may wish to pursue.)

 

Investigators are not permitted to submit more applications in an application cycle than the number in which they are allowed to participate if all applications were successful. Practically, this means that in any given year:

O Applicants for the role of coordinator cannot have their name on any other application submitted to the foundation.

O A member of a current Leducq network, which is expected to continue the following year, can be included in only one application to the foundation.

O An investigator not currently participating in a Leducq network can submit a maximum of either one application where his/her role will be that of coordinator, or two applications for that of member.

O An investigator who is a member of two Leducq networks can participate in a network application only when one of the networks of which he/she is a member comes to the end of its five-year term.

 

https://www.fondationleducq.org/international-networks-of-excellence-how-to-apply/how-to-apply/

https://www.fondationleducq.org/wp-content/uploads/2021/06/Program-Description-2021.pdf

 

 

Thursday 17 February 2022

The Alzheimer's Drug Discovery Foundation (ADDF):  Diagnostics Accelerator-Peripheral Biomarkers Program


 

The Diagnostics Accelerator is accepting applications on a rolling basis.

Exploratory awards: up to approximately $250,000

Proof-of-principle awards: up to $500,000

Validation awards: Award amounts will be based on stage and scope of research

 

Modalities: Blood and other peripheral markers, including saliva, urine, and ocular biomarkers are encouraged. The development of Cerebrospinal fluid (CSF) and neuroimaging biomarkers will not be considered for this program; however, we encourage the use of these modalities to validate proposed biomarkers.

Biomarker targets: Proposed approaches will be evaluated on biological plausibility linking the biomarker to disease pathophysiology. Examples of target areas of interest include, but are not limited to:

  • Vascular injury and blood-brain barrier integrity
  • Neuroinflammation
  • Neuroprotection and Neurodegeneration
  • Biomarkers of interest in fronto-temporal degeneration (FTD)
  • Protein misfolding
  • Synaptic integrity and/or activity
  • Mitochondria and metabolic function

Other novel approaches that are supported by compelling evidence that demonstrate a rational biological connection to the disease process are encouraged.

Sample sharing program: Clinical validation of a biomarker requires well characterized samples across multiple cohorts. The Diagnostics accelerator has partnered with Janssen/Shionogi, Eisai and Roche pharmaceuticals to make available samples from their clinical trials to our researchers.

The peripheral RFP is open to all biomarker categories that will advance drug development for Alzheimer's and related dementias. The expected context of use, which defines a biomarker's intended use clinically as a diagnostic or in drug development, should be described in the application. These categories, as defined by the FDA, include diagnostic, monitoring, predictive, prognostic, pharmacodynamic/response, safety, and susceptibility/risk biomarkers. Additionally, the applicant should articulate where in the path to commercialization the study falls and what is the proposed plan forward.

 

The following types of projects will be supported through this RFP:
  1. Exploratory awards will support pilot studies that aim to test the utility of an existing fluid biomarker approach for the first time in an Alzheimer's disease or related dementia population. These projects should already have preliminary human data from another disease indication. A limited number of awards will be considered in this category.
    Generally, projects at this stage will be awarded up to approximately $250,000 based on stage and scope of research. However, this is not a cap and higher funding levels will be considered if the proposed budget is well justified.
  2. Proof-of-principle awards will support exploratory analyses of biomarkers at a small scale (e.g., 50-100 human samples) that are supported by human data demonstrating that the candidate markers correspond with disease pathophysiology. Preliminary assay validation data for the proposed studies should be included.
    Generally, projects at this stage will be awarded up to $500,000 based on stage and scope of research. However, if there is a compelling reason to go above this level, please justify this in your full proposal if invited.
  3. Validation awards will support biomarkers that need to be tested at a larger scale (e.g., 500-1000 samples) and are supported by a significant body of human data demonstrating that the biomarker(s) correspond with disease pathophysiology. Applicants should be able to address how validation studies would move the biomarker towards the clinic and should define their strategies for regulatory approval and commercial scale-up. Assays should be well developed. Proposals should consider compatibility with existing sampling infrastructure, scalability, and intellectual property position, and standard operating procedures should be in place. Validation studies should compare peripheral analytes to quantitative measurements using PET and/or CSF, going beyond comparisons to cognition alone. Award amounts will be based on stage and scope of research.

Projects that succeed in the exploratory or proof-of-principle stage may be eligible for follow-on funding.

https://www.alzdiscovery.org/research-and-grants/funding-opportunities/diagnostics-accelerator-peripheral-biomarkers-program

Monday 28 February 2022

Financial support to the organization of scientific events


 

 

More information : please download the document

Monday 28 February 2022

ARSEP: Working Visits


 

To facilitate exchanges between clinical centres and/or laboratories involved in MS. Travel may be within, to, or from France.

  • The training period can be up to 6 months.
  • Funding requests for up to 6.000 € to cover travel and accommodation are permitted.

Deadline: No deadline - throughout the year

https://www.arsep.org/fr/220-calls-for-proposals.html

https://www.arsep.org/library/media/other/Scientifique/Regulation-Working-visits-Travel-Grants-website.pdf

Tuesday 01 March 2022

The France-Stanford Center for Interdisciplinary Studies


 

The France-Stanford Center for Interdisciplinary Studies, founded in partnership with the French Ministry of Foreign Affairs, bridges the disciplines of the Humanities, Social Sciences, Engineering, Business and Law, addressing issues of significance for France and the U.S. from a broad range of perspectives. It is part of Stanford Global Studies in the School of Humanities and Sciences.

 

Collaborative research projects

The France-Stanford Center for Interdisciplinary Studies invites proposals for collaborative research projects to be held during academic year 2022-23 (September 1, 2022 to August 31, 2023).

Priority will be given to projects with the potential to develop new collaborations involving junior researchers, and to those leading to collaborative work on interdisciplinary issues. Applications must be submitted jointly by researchers affiliated with a French institution and researchers in any Stanford department, as long as they are eligible to serve as principal investigators.

Deadline for applications: March 1, 2022

Budget: Projects will be funded up to $15,000 (USD).

Duration: One academic year (September 1 - August 31). Project extensions are available in some cases.

Expenses: The grant may be used for travel, lodging, and living costs, as well as research-related services. The grant may not be used for purchasing equipment, tuition fees, conference registration fees, salary payments nor publishing fees.

https://francestanford.stanford.edu/funding/collaborative-research-projects

https://francestanford.stanford.edu/sites/francestanford/files/media/file/collaborative_research_cfp_2022-23.pdf

francestanford@stanford.edu

 

Visiting Junior Scholar Fellowship

The France-Stanford Center Visiting Junior Scholar Fellowship is open to scholars who have completed a Ph.D. no more than three years from the date of applying for the fellowship and who hold a tenure-track/permanent position or a postdoctoral position. These may be Stanford-based scholars seeking a research visit at a French institution or scholars based in a French institution seeking a research visit at Stanford.

The France-Stanford Center for Interdisciplinary Studies invites proposals for junior scholar fellowship research projects to be held during academic year 2022-23 (September 1, 2022 through August 31, 2023).

Deadline for applications: March 1, 2022

Eligibility: Scholars affiliated with Stanford University or a French Institution and who have completed a Ph.D. no more than three years from the date of applying to the fellowship and postdoctoral students.

Budget: Visits will be funded up to $7,000 (USD).

Duration: Two to four months.

Expenses: The grant may be used for travel, lodging, and living costs. The grant may not be used for purchasing equipment, supplies or software, tuition fees, conference registration fees, salary payments nor publishing fees.

https://francestanford.stanford.edu/funding/visiting-junior-scholar-fellowship

https://francestanford.stanford.edu/sites/francestanford/files/media/file/Visiting%20Junior%20Scholar%20Fellowship%20CFP%20%282022-23%29_updated.pdf

francestanford@stanford.edu

Wednesday 02 March 2022

Bpifrance : Appel à Projets "Evaluation du bénéfice médical et / ou économique des dispositifs médicaux numériques ou à base d’intelligence artificielle"


 

L’objectif de cet appel à projets est de soutenir les projets d’évaluation visant à évaluer le bénéfice des dispositifs médicaux numériques ou à base d’intelligence artificielle. Les résultats des projets devront directement permettre de justifier l'utilisation en pratique du dispositif testé.

Par dispositif médical numérique on entendra tout dispositif médical (DM), dispositif médical implantable actif (DMIA) ou dispositif médical de diagnostic in vitro (DMDIV) dont la composante numérique représente la part prépondérante de l’actif, ou la part prépondérante de la proposition de valeur.

 

La date limite de dépôt des dossiers est fixée au 2 mars 2022 à 12 heures.

 

Le projet doit :

  • présenter une demande d’aide d‘un montant compris entre 100000 Euros et 2 500 000 Euros. Les travaux associés à la demande d’aide ne doivent pas avoir commencé avant le dépôt de la demande d’aide ;
  • Les projets dont le montant d’aide sollicitée est inférieur à 200 000 Euros doivent être mono-partenaires ; les établissements de santé doivent dans ce cas être intégrés dans la catégorie “sous-traitance” de l’annexe financière.
  • proposer une assiette éligible de travaux qui ne fait pas ou n’a pas fait l’objet de financements publics hors du cadre du présent appel à projets : par l’État, les collectivités territoriales, l’Union européenne ou leurs agences ;
  • se dérouler sur une durée comprise entre 12 et 48 mois à compter d'une date postérieure à la clôture de l'appel à projets
  • Le projet doit exclusivement porter sur l'évaluation médicale et/ou économique du dispositif, à l’exclusion du développement technologique algorithmique ou d'apprentissage sur de nouvelles données.

 

Les projets d’évaluation peuvent porter sur une technologie :

  • qui n’est pas encore sur le marché. Dans ce cas, le porteur du projet devra démontrer que ce développement technologique a été réalisé suivant un système de management de la qualité permettant d’obtenir sa mise sur le marché à l’horizon de la fin de l’étude. Ces projets incluront dans le dossier de candidature le rapport d’audit interne permettant d’attester de la mise en place du système de management de la qualité ; ou :
  • qui est déjà sur le marché et a déjà obtenu un marquage CE et/ou FDA. Ces projets incluront dans le dossier de candidature les documents attestant de l’obtention du marquage CE / FDA. Dans les deux cas, les documents acceptés sont précisés dans le cahier des charges.

 

Porteur(s) du projet :

  • Dans le cas d’un projet monopartenaire : être porté par un établissement unique responsable du développement du dispositif. Les coûts des établissements de santé partenaires de l’étude sont alors à intégrer dans la catégorie sous-traitance ;
  • Dans le cas d’un projet collaboratif : être porté par un consortium composé d’au moins un établissement de santé et de l’établissement en charge du développement du dispositif, dans la limite de 3 partenaires ;
  • Le porteur ou l’établissement chef de file doit être l’établissement responsable du développement technologique ;
  • Le porteur ou l’établissement chef de file doit démontrer la mise en œuvre effective d’un système de management de la qualité : marquage CE ou FDA ou rapport d’audit interne ;
  • Le porteur ou l’établissement chef de file doit être une personne morale enregistrée en France ;
  • Il n’y a pas de contraintes sur la nature des établissements : public / privé / associations / fondations ;

 

Type de dépenses :

  • Salaires et charges : Salaires chargés du personnel du projet (non environnés) appartenant aux catégories suivantes : chercheurs (post-doc inclus), ingénieurs, techniciens.
  • Frais connexes : Montant forfaitaire des dépenses de personnel (salaires chargés non environnés) et/ou d’équipements (amortissements), selon les cas. 4
  • Coûts de sous-traitance : Coûts de prestations utilisées exclusivement pour l'activité du projet, y compris évaluation. (cible : 60% max des coûts projet dans le cas général)
  • Contribution aux amortissements : Coûts d'amortissements comptables des instruments et du matériel de R&D au prorata de leur utilisation dans le projet. Exemple : pour un équipement amorti de façon linéaire sur une durée de 10 ans, et utilisé durant 2 ans pour le projet, le montant éligible à une aide sera égal à 2/10 du montant total de l’investissement dans cet équipement.
  • Coûts de refacturation interne : Sur la base de modalités de calcul détaillées et de la certification par un commissaire aux comptes ou expert-comptable. Pour des entreprises avec le même SIREN.
  • Frais de mission : Frais réels des déplacements liés à la réalisation du projet.
  • Autres coûts : Autres frais d'exploitation directement liés à l'activité du projet. (consommables non amortis dans les comptes)

 

https://www.bpifrance.fr/nos-appels-a-projets-concours/appel-a-projets-evaluation-du-benefice-medical-et-ou-economique-des-dispositifs-medicaux-numeriques-ou-a-base-dintelligence-artificielle

Thursday 24 March 2022

INCa: PLBIO 2022


 

L'appel à projets libres « Biologie et Sciences du Cancer » est ouvert à l'ensemble des domaines de la recherche en biologie fondamentale et des disciplines scientifiques participant à la lutte contre le cancer afin de permettre l'acquisition de nouvelles connaissances sur les pathologies tumorales, de développer de nouveaux outils et d'ouvrir de nouvelles perspectives thérapeutiques.

La soumission de projets ayant des contributions disciplinaires autres que la biologie est fortement encouragée. La partie biologique doit être significativement développée et pertinente.

 

La durée des projets est de 36 ou 48 mois.

 

Des lettres d'intention : 2 novembre 2021 à 16h00,

Des projets finalisés : 24 mars 2022 à 16h00

 

Recommandations : Cet appel à projets est très compétitif, il est donc vivement conseillé aux porteurs de projets de respecter les objectifs de l'appel à projets et de présenter des projets répondant aux critères suivants :

  • Une pertinence scientifique vis-à-vis du cancer ;
  • Des projets originaux dans l'hypothèse et l'approche ;
  • Une méthodologie robuste, incluant des approches alternatives et des études mécanistiques ;
  • Des projets matures présentant une preuve de concept (données préliminaires).

 

La subvention L'Institut national du cancer pourra financer :

  • Des frais de personnel (le personnel permanent peut être imputé sur les dépenses éligibles du projet à l'exclusion des fonctionnaires
  • d'état, hospitaliers ou territoriaux). Le financement de post­ doctorants peut être demandé ; celui de doctorants n'est en revanche pas éligible;
  • Des frais de fonctionnement notamment :

-des consommables liés à la réalisation du projet (petit matériel, produit de laboratoire, tests) à l'exception des consommables de bureau qui relèvent des frais de gestion ;

-des frais de propriété intellectuelle de brevets ou licences induits par la réalisation du projet ;

-des frais liés à la publication des résultats financés y compris, par exemple, les surcoûts éventuellement appliqués pour la publication des articles en accès ouvert ;

-des frais de déplacement ou de missions des personnels permanents ou temporaires affectés au projet (congrès, colloque, monitoring d'ARC/TEC, etc) ;

-des frais d'organisation de réunions, séminaires en lien avec le projet et dans la limite de la durée du projet (location de salle et location de matériel) à l'exception des frais de réception qui relèvent des frais de gestion ;

-des prestations de services : le bénéficiaire de la subvention peut faire exécuter des prestations par des tiers extérieurs au projet ;

-des dépenses justifiées par une procédure de facturation interne : ces dépenses correspondent à des prestations ayant donné lieu à une tarification et traçables en comptabilité, réalisées par une entité (service, département, etc..) du bénéficiaire. Cette facturation interne doit être proportionnée à l'utilisation effective des prestations pour les besoins du projet ;

  • De l'équipement pour un montant inférieur à 150 K€ TTC. Ce seuil de 150K€ s'applique par achat unitaire d'équipement (et non pas sur le montant total des dépenses d'équipement). De plus, le montant total des dépenses d'équipement ne pourra être supérieur à 30 % du montant de la subvention allouée par l'Institut
  • Des frais de gestion : à hauteur de 8 % maximum du coût total des dépenses éligibles (personnel, fonctionnement, équipement) effectivement payées. Les frais de gestion ont un caractère forfaitaire et recouvrent :

-les frais d'administration générale en lien avec la gestion administrative et le suivi du projet (tels que notamment le temps administratif dédié aux conventions de reversement des fonds, suivi des financements des équipes participantes), l'achat de consommables de bureau, papeterie, etc. ;

-les frais de réception des réunions, colloques et séminaires (plateaux repas, cocktail) ;

https://projets.e-cancer.fr/